Mechanisms of adipose tissue redistribution with rosiglitazone treatment in various adipose depots.
Treatment with thiazolidinediones (TZDs) improves glucose homeostasis by increasing insulin sensitivity, but it also leads to weight gain. Our hypothesis was that, in individual adipose depots, there is depot specificity for lipid storage and energy expenditure genes after TZD treatment. After 5 weeks of rosiglitazone treatment on Otsuka Long-Evans Tokushima Fatty (OLETF) rats, an animal model of type 2 diabetes mellitus with obesity, and Long-Evans Tokushima Otsuka rats as controls, we measured changes in lipid storage and energy expenditure gene expression in various adipose depots, such as mesenteric and nonmesenteric adipose tissues (subcutaneous, epididymal, and retroperitoneal). Mesenteric fat masses did not change after TZD treatment in OLETF rats, but nonmesenteric fat masses increased. Messenger RNA expression of lipid storage genes increased in nonmesenteric fat, but energy expenditure gene expression increased in mesenteric fat after rosiglitazone treatment. In conclusion, our findings suggest that TZD treatment may be associated with the depot-specific effects of lipid storage and energy expenditure genes on fat redistribution in individual adipose tissues in OLETF rats.
Kang
Jun Goo
JG
Department of Endocrinology and Metabolism, Hallym University School of Medicine, Hallym University Sacred Heart Hospital, Dongan, 431-070, South Korea.
Park
Cheol-Young
CY
Ihm
Sung-Hee
SH
Yoo
Hyung Joon
HJ
Park
Heesoon
H
Rhee
Eun Jung
EJ
Won
Jong Chul
JC
Lee
Won Young
WY
Oh
Ki Won
KW
Park
Sung Woo
SW
Kim
Sun Woo
SW
D050154:Adiposity / Q000187:drug effects*; D000818:Animals; D001483:Base Sequence; D001786:Blood Glucose / Q000032:analysis; D017931:DNA Primers; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy / Q000473:pathology; D004195:Disease Models, Animal; D004734:Energy Metabolism; D020869:Gene Expression Profiling; D005951:Glucose Tolerance Test; D007004:Hypoglycemic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D007328:Insulin / Q000097:blood; D008055:Lipids / Q000097:blood; D051381:Rats; D020318:Rats, Long-Evans; D020133:Reverse Transcriptase Polymerase Chain Reaction; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000494:pharmacology* / Q000627:therapeutic use
D001786:Blood Glucose; D017931:DNA Primers; D007004:Hypoglycemic Agents; D007328:Insulin; D008055:Lipids; D045162:Thiazolidinediones; D000077154:Rosiglitazone